U.S. health authorities said Thursday that 16- and 17-year-olds should get a booster dose of Pfizer's COVID-19 vaccine once they're six months past their last shot.
The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified with the discovery of the worrisome new omicron variant.
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech. And hours later, the Centers for Disease Control and Prevention lifted the last barrier — saying those teens should get their booster as soon as it's time.
CDC Director Rochelle Walensky told The Associated Press the boosters are important considering that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected.”
“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commissioner, said in a statement.
The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccination or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose.
Vaccinations for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5- to 11-year-olds had gotten a first dose.
The extra-contagious delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different omicron mutant. But there’s strong evidence that boosters offer a jump in protection against delta-caused infections, currently the biggest threat.
Complicating the decision to extend boosters to 16- and 17-year-olds is that the Pfizer shot -- and a similar vaccine made by Moderna -- have been linked to a rare side effect. Called myocarditis, it’s a type of heart inflammation seen mostly in younger men and teen boys.
The FDA said rising COVID-19 cases in the U.S. mean the benefits of boosters greatly outweighed the potential risk from the rare side effect, especially as the coronavirus itself can cause more serious heart inflammation.
Health officials in Israel, which already gives boosters to teens, have said the side effect continues to be rare with third doses.
A U.S. study this week offered additional reassurance. Researchers from children’s hospitals around the country checked medical records and found the rare side effect usually is mild and people recover quickly. The research was published Monday in the journal Circulation.
___
Associated Press reporter Matthew Perrone contributed to this report.
In 2015, 193 parties signed the Paris Agreement. In doing so, they agreed to pursue efforts to limit the average global temperature increase to 1.5° Celsius - or 2.7 degrees Fahrenheit -above pre-industrial levels. To be clear, our planet is already 1.1 degrees hotter than it was 150 years ago. But most scientists agree that an increase of just .4 more degrees will drastically change the world. However, it would continue to be livable. Things do get murky, though, as the projections increase above that.
Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to break down how people can protect themselves and family amid the uncertainty of the new Omicron COVID-19 variant. Caudle emphasized the importance of getting vaccinated against COVID-19 with so much still uncertain about the pandemic. "We have to remember delta variant is still here in the United States," she said. "We're still losing too many people every single day to this virus."
Jill and Carlo discuss what appears to be the beginning of the end of Roe v. Wade, another victim dies following the school shooting in Michigan, Omicron in the U.S., Trump's Covid chronology and more.
Was it a coincidence that the omicron coronavirus variant evolved in a region with low vaccination rates? Cheddar speaks with epidemiologist Dr. Eric Feigl-Ding on the topic.
Astra founder, chairman, and CEO Chris Kemp spoke to Cheddar's Kristen Scholer about his company's first successful launch into orbit last month, becoming the fastest space company to reach orbit using a privately developed liquid-fueled rocket. He also noted that the company's priority is to "improve life on Earth from space" by rapidly increasing the number of low-orbiting satellites to do everything from connecting people to monitoring weather patterns.
Stocks closed at session lows Wednesday as investors grew skittish over the first reported case of the COVID-19 omicron variant in California. Josh Sailar, Partner at Blue Zone Wealth Advisors, joins Cheddar News' Closing Bell to discuss investor worry over the new variant, the Fed dropping the word 'transitory' to describe inflation and potentially speeding up their asset tapering timeline, 2022 predictions, and more.
As cases of the COVID-19 Omicron variant continue to pop up, including the first U.S. case in California, how will domestic holiday travel be impacted? That part of the travel sector has mostly recovered from the year-long pandemic rout, while business travel continues its slump. But could a new variant bring new lockdowns and domestic restrictions? Clint Henderson, Senior News Editor at The Points Guy, joins Cheddar News' Closing Bell to discuss what the omicron variant means for holiday travel, best practices for passengers traveling through airports, and more.
Over the Thanksgiving holiday, Elon Musk warned SpaceX employees in a leaked email that the company could be forced to file Chapter 11 bankruptcy if its raptor engine program fails. Musk then commented on the previous statement adding the detail that a recession could make such a bankruptcy possible.
